Arkansas Cardiology Symposium

Registration Form

7:00 a.m. Registration, Continental Breakfast, and Exhibits


7:50 a.m. Welcome and Opening Remarks, Invocation

    Jay Geoghagan, MD, FACC
    David Jones, MD, FACC
    Steve Greer, MD, FACC, FACP

8:00 a.m. Dysautonomia

Steve Greer, MD, FACC


8:30 a.m. Screening Consequences: Coronary and Aortic Calcification

Christen Johnson, MD

9:00 a.m. Interpretation of Non-Invasive Testing

    Kirby Von Edwin, MD, FACC

9:30 a.m. Morning Break and Exhibits

9:45 a.m. Patient Experience: TAVR (Video)

    Aaron Strobel, MD

10:15 a.m. Lipid Management: Statins and Alternatives

    Charles Caldwell, MD, FACC

10:45 a.m. Diabetes Drugs for Non-Diabetics with Cardiac Risk/Disease (SGLT2i/GLP-1)

    Ramey Marshell, MD

11:15 a.m. Peripheral Artery Disease: Basics for the PCP

    Hani Turkmani, MD

11:45 a.m. Lunch and Exhibits

12:45 p.m. EKG Rapid Fire

    Jay Geoghagan, MD, FACC

1:15 p.m. A Review of the Clinic Management of Acute/Subacute TIA/Stroke

    Joe Hackler, DO, FACC

1:45 p.m. Vitamins and Supplements: What is evidence in Heart Disease

    Tom Conley, MD, FACC, FSCAI

2:15 p.m. Afternoon Break and Exhibits

2:30 p.m. Coronary Artery Disease

    Faheem Beg, MD, FACC

3:00 p.m. Left Atrial Appendage Devices

    Blake Norris, MD, FACC

3:30 p.m. Adjourn

Objectives

  • Review ACC/AHA guidelines related to the treatment of poorly controlled hypertension.
  • Review options for hypertension management.
  • Discuss types of Aortopathy.
  • Review known causes of Aortopathy.
  • Discuss the appropriate duration of dual antiplatelet therapy after coronary stenting.
  • Review the data for short- and long-term dual anti-platelet therapy.
  • Discuss sports recommendations in post-COVID patients.
  • Know the rationale and suggested use of the AHA/ACC Eligibility and Disqualification Recommendations for Competitive Athletes.
  • Review the current technological advances in the interventional management ofstructural heart diseases, including minimally invasive heart valve interventionson aortic, mitral and tricuspid disease.
  • Discuss improvements to safety, quality and patient satisfaction surroundingnon-surgical structural procedures.
  • Discuss risk factors for Women with known coronary artery disease.
  • Evaluate treatment options for Women with known coronary artery disease.
  • Explain how managing health behaviors and risk factors are an important aspectof lowering the risk of cardiovascular disease.
  • Discuss exercise strategies for patients with known cardiac disease.
  • Review clinical treatment strategies to address patients with Heart Failure withReduced Ejection Fraction (HFrEF).
  • Assess the implications of new treatments for HFrEF.
  • Review clinical treatment strategies to address patients with Heart Failure withpreserved Ejection Fraction (HFpEF).
  • Assess medications used to treat HFpEF.
  • Review normal and abnormal ECG findings.
  • Determine appropriate treatment options for specific arrhythmias.
  • Review clinical literature relating to novel anticoagulant medications.
  • Discuss the complications of atrial fibrillation and the reasoning behind theprescribing of an anticoagulant.
  • Review Dietary trends and discuss the role they play in overall CardiovascularHealth.